Overview of Marine Bioactive Peptides (MBAPs) against HIV: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Jameel Mohammed Al-Khayri
,
Waqas Asghar
,
Sipper Khan
,
Aqsa Akhtar
,
Haris Ayub
,
Nauman Khalid
,
Fatima Mohammed Alessa
,
Muneera Qassim Al-Mssallem
,
Adel Abdel-Sabour Rezk
,
Wael Fathi Shehata

Marine bioactive peptides (MBAPs) that are present in many marine species, including fish, sponges, cyanobacteria, fungi, ascidians, seaweeds, and mollusks, have gained widespread attention for their health-promoting benefits. MBAPs obtained from marine species have ameliorating potential against many health conditions, such as hypertension, diabetes, obesity, HIV, cancer, oxidation, and inflammation. Various research studies have indicated that MBAPs can be utilized as novel lead structures for the treatment of HIV in conjunction with pharmaceuticals and functional foods owing to their potential therapeutic, and antiretroviral (ARV) activities.

  • bioactive peptides
  • anti-HIV
  • drugs
  • marine organisms
  • antiretroviral agents

1. Techniques Used for the Commercial Preparation and Purification of Marine Bioactive Peptides

MBAPs have been extracted from various sources, including fish, algae, crustaceans, and mollusks, in addition to various marine waste products, such as shells, substandard muscles, viscera, trimmings, and skins [1]. The bioactive peptides (BAPs) are either procured from proteins during digestion and food processing or are already present in the products prior to the processing operations [2]. The latter consist of both ribosomal BAPs, as well as their non-ribosomal counterparts (depsipeptides, cyclic peptides, and non-natural amino acid residues) [3]. Figure 1 is a schematic representation of the stages involved in the preparation and purification of marine peptides.
Marinedrugs 20 00477 g002 550
Figure 1. Preparation and purification of marine peptides.
Different techniques have been used for the extraction of these peptides, such as organic solvents and acid/alkaline solutions. Extraction is followed by isoelectric precipitation, although, this results in the production of peptides with potentially adverse effects on the environment. Additionally, it is often accompanied by a high cost of production, leading to a longer purification process [4][5]. Recent research on antimicrobial marine peptides, or their fractions thereof, are reported to have a molecular weight <10 kDa and a high degree of antimicrobial activity [6]. 

2. Marine Sponge-Derived Bioactive Peptides against HIV

Marine sponges are soft-structured, filter-feeding, bioactive component-rich, aquatic invertebrate parazoans from the phylum Porifera, and act as diversified habitats for numerous marine species [21]. Sponges contain diverse biomolecules of varying chemical and structural characteristics that exhibit various bioactive attributes [22]. This is proven by the fact that out of nine FDA-approved marine drugs, four are contributed by sponges [23]. Research reports suggest that many of the bioactive metabolites isolated from sponges are generated by their functional enzyme clusters and the microorganisms associated with these sponges [24].
Koshikamides from the sponges of Theonella sp. have been reported to exhibit anti-HIV activity. In this regard, relative to their linear counterparts, the cyclic koshikamides F and H inhibited HIV entry with IC50 values of 2.3 and 5.5 µM, respectively, when tested in a single round HIV-1 infectivity assay against a CCR5-using viral envelope [25][26]. Additionally, the peptides were evaluated for their cytotoxicity against various target cell lines, including a control kidney cell line (BSC-1), a human colon tumor cell line (HCT-116), and the target cell line TZM-bl. Favorably, neither koshikamide F nor koshikamide H exhibited cytotoxicity toward any of the target cell lines at these concentrations [25]. Although, koshikamide H was found to exhibit moderate cytotoxicity against the HCT-116 target cell line with an IC50 value of 10 µM [27]. The anti-HIV activity of the cyclic koshikamides F and H has been attributed to the presence of the 10 AA residue lactone ring in their structures, a characteristic absent in the linear analogs of these peptides [28]. Furthermore, koshikamide F has been proven to be slightly more potent in terms of anti-HIV activity, owing to the distinctive macrolactone conformation induced by the presence of the unsaturated pyrrolidinone residue Apdp [25].
Depsipeptides (also termed cyclodepsipeptides) with unique non-proteinogenic amino acid combinations inherently incorporated into their structures are isolated from various species of marine sponges and are of particular interest as powerful molecules aimed at drug development against HIV [23]. Callipeltin A (source: Callipelta sp. and Latrunculia sp.) and neamphamide A (source: Neamphius huxleyi) have also been proven to prevent the replication of HIV [29]. Callipeltin A, in an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay, inhibited HIV-1-induced (Lai strain, X4 tropic) cytopathic effects in CEM4 lymphocytic cell lines at an EC50 value of 0.01 μg/mL, and a TC50 value of 0.29 μg/mL [30]. Additionally, the structural similarities to the potent antiviral family of compounds called didemnins might also imply that callipeltin A possesses anti-HIV activity [31]. Similarly, neamphamide A demonstrated HIV-inhibitory activity in a 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) cell viability assay in a human T-cell line CEM-SS infected with HIV-1RF at an IC50 value of 28 nM, and a TC50 value of 260 nM [30]. Furthermore, homophymine A, a depsiundecapeptide from a New Caledonian species of marine sponges, Homophymia sp. demonstrated cytoprotective activity against HIV infection. The anti-HIV activity was evaluated by an XTT cell viability assay in HIV-1-infected cells (IIIB strain). An assessment at seven days post-infection indicated that the compound inhibited HIV-1 infection production with an IC50 value of 75 nM [32][33]. Also, a TC50 value of 1.19 μM was recorded against host cells when direct cytotoxic measurements of homophymine A were undertaken [32][33].
Anti-HIV activity has also been recorded for mirabamides E–H derived from the marine sponges Stelletta clavosa, along with the already recognized mirabamides A–D isolated from the sponge Siliquariaspongia mirabilis. The activity of mirabamides was tested using HIV-1 neutralization assays against two viral strains, HXB2 (T-cell-tropic) and SF162 (macrophage-tropic), in addition to an HIV-1 envelope-mediated cell fusion assay to ascertain whether these peptides act to prevent the entry of the virus during the initial stages of the infection [30][34]. Mirabamides A, C, and D exhibited significant inhibitory activity against HXB2 infection of the TZM-bl host cells (involved in the expression of CXCR4, CCR5, and CD4) with IC50 values of 140 nM, 140 nM, and 190 nM, respectively, while mirabamide B was relatively less effective with an IC50 value of >50 μM [30][34]. Comparatively, mirabamides A, C, and D were relatively less potent towards SF162 (IC50 values of 400 nM, 1 μM, and 1 μM, respectively), while mirabamide B once again exhibited weak inhibitory activity toward SF162 [30][34]. As mirabamides A, C, and D have been found to inhibit HIV in both the aforementioned neutralization and fusion assays, it may be surmised that these peptides can act at the initial stages of HIV entry into the host cell, preventing viral entry and subsequent fusion [30][34]. Likewise, pseudotyped viruses with an enveloped HIV-1 strain when tested in single-round infectivity assays against the new cyclodepsipeptides mirabamides E–H (isolated from the hairy olives sponge S. clavosa), in parallel with mirabamide C, exhibited significant antiviral replication activity in genital epithelial cells (expressing CCR5 and CD4 HIV-1 coreceptors) with IC50 values of 121, 62, 68, and 41 nM, for mirabamides E–H, respectively. Therefore, these compounds also seem to be inhibitors of viral entry during the initial stages of infection by virtue of their binding capabilities to the HIV-1 envelope glycoprotein for inhibition of viral fusion into the host cell membrane [35].
Along with the previously reported depsipeptides with HIV-inhibitory activity (such as mirabamides) from S. clavosa, two new depsipeptides, namely stellettapeptin A (EC50: 23 nmol/L) and stellettapeptin B (EC50: 27 nmol/L) were discovered, exhibiting potent HIV-inhibitory activities [23]. For this study, the anti-HIV activity of stellettapeptins was evaluated in an XTT-based cell viability assay by using the human T-cell line CEM-SS infected with HIV-1RF. After an incubation period of 6 days, the incubated compounds were found effective to inhibit the cytopathic effect of HIV-1. The toxicity of these depsipeptides against the host cells was observed with IC50 values of 367 and 373 nM, respectively [36].
Microspinosamide, a tridecadepsipeptide from the sponge Sidonops microspinosa, is another cyclic depsipeptide with an inhibitory effect against cytopathic action of HIV-1 infection in an in vitro XTT-based assay with an EC50 value of 0.2 μg/mL [37]. Similarly, theopapuamide B, isolated from the bacteria symbiosis sponges Theonella swinhoei and S. mirabilis exhibited anti-HIV activity in an in vitro single-round HIV-1 infectivity assay against HIV-1 SF162 envelope pseudotyped viruses with an IC50 value of 0.8 µg/mL [37]. Celebeside A from S. mirabilis has similarly been attributed with HIV-1 neutralization activity with an IC50 value of 1.9 µg/mL in a single-round infectivity assay [37].
One of the primary reservoirs of latent infection is the CD4+T cell containing integrated and transcriptionally silenced HIV-1 proviruses [38]. The activation of these resting cells, particularly after prolonged periods of dormancy, results in proviral gene expression of HIV-1 and consequent renewal of viral infection [39]. The increasing emphasis has therefore been on exploring therapeutic interventions aimed at complete elimination of the latent proviruses (sterilized cure) [40]. Of particular research, interest is what is commonly termed as the ‘shock and kill’ strategies, whereby the transcription of HIV-1 proviruses present in resting CD4+ T reservoir cells is de-repressed with the aid of small molecule drugs for the production of replicating virus, which could be inhibited through simultaneous administration of highly active antiretroviral therapy (HAART) [41]. The identification of various latency reversal agents (LRAs) capable of activating HIV-1 proviral gene expression from marine sponge Phorbas sp. has been a significant development in this context [39]. The latency reversal activity in the majority of LRAs can be attributed to their ability to activate adenosine 3′,5′-monophosphate (AMP), and protein kinase C (PKC) signaling [42]. The structures of sponge-derived peptides are demonstrated in Figure 2.
Marinedrugs 20 00477 g003a 550Marinedrugs 20 00477 g003b 550Marinedrugs 20 00477 g003c 550Marinedrugs 20 00477 g003d 550Marinedrugs 20 00477 g003e 550Marinedrugs 20 00477 g003f 550Marinedrugs 20 00477 g003g 550Marinedrugs 20 00477 g003h 550
Figure 2. Chemical structures of MBAPs derived from marine sponges. (a) koshikamide F, (b) koshikamide H, (c) mirabamide A, (d) mirabamide C, (e) mirabamide D, (f) mirabamide E, (g) mirabamide F, (h) mirabamide G, (i) mirabamide H, (j) stellettapeptin A, (k) stellettapeptin B, (l) homophymine A, (m) callipeltin A, (n) neamphamide A, and (o) mirabamide B.

3. Marine Cyanobacteria-Associated Compounds with Anti-HIV Properties

Cyanobacteria are photosynthetic bacteria abundantly observed in nature [43]. They contain a large variety of toxins along with several bioactive compounds with potential bioactive attributes such as antitumor, anticancer, antimicrobial, antifungal, anti-inflammatory, and protease inhibition characteristics.
Cyanovirin-N (CV-N), (Figure 2) an 11 kDa protein derived from the cyanobacteria Nostoc ellipsosporum has been tested as an anti-HIV compound (preclinical development) [44]. The IC50/EC50 values for native CV-N against various HIV-1 isolates range between 0.1 and 36.8 nM, while against HIV-2 isolates, the IC50/EC50 values range between 2.3 and 7.6 nM [45][46]. In a recent research study, all three forms (mixed, dimer, monomer) of a recombinant version of CV-N (rCV-N) (monomeric mass: 11.962 kDa), exhibited significant anti-HIV activity with an IC50 range of 0.5−5 nM, a therapeutic index (TI) of ~1000–10,000 in vitro, negligible cytotoxicity of approximately 5 μM, and low endotoxins (mixed form refers to a mixture of monomer, dimer and higher-order oligomers together). TZM-bl cells were infected with HIV-1NL4-3 for the assessment of anti-HIV activity of the rCV-N forms, while their cytotoxicity was determined by an MTT cell proliferation assay. This anti-HIV activity can be attributed to the capability of CV-N to interfere with the fusion of HIV with the CD4+ cell membrane [47].
CV-N has demonstrated specific and strong interaction capabilities with the viral envelop glycoprotein gp120 through N-linked oligosaccharides with high mannose content, particularly the glycans Man-8 and Man-9 [48]. This consequently prevents the binding of the gp120 to the host CD4 T-cell receptor, in addition to the chemokine CCR5 and CXCR4 co-receptors, thereby inhibiting both the viral entry and the cell-to-cell fusion and transmission [49]. Owing to its excellent stability, lower toxicity, broad-spectrum antiviral activities, and highly specific binding to oligosaccharides, CV-N has the potential to be a class-leading compound for the prevention of sexual transmission of HIV [50].
Similarly, microvirin (MV-N), isolated from the bloom-forming cyanobacterium Microcystis aeruginosa, is another compound with anti-HIV potential [15]. MV-N is a 14.3 kDa protein and has high specificity for α(1-2)mannobiose at the termini of branched high mannose-type glycans on the viral surface [16]. MV-N, like CV-N, can neutralize a broad range of clinical isolates, and laboratory-adapted strains with low nanomolar potency against most HIV-1 group M clades of various subtypes and tropics [46] with IC50 values ranging between 2.1 and 167 nM. MV-N was much more active against HIV-1 isolates A and B when compared to CV-N [51]. MV-N, therefore, is active in the reduction of initiation markers, including CD25, CD69, and HLA-DR, preventing the formation of syncytium between cells infected with HIV-1, and healthy CD4+ T cells, also inhibiting viral replication [51][52]. Furthermore, as the research study by Huskens et al. evidenced, MV-N induced negligible cytotoxicity in MT4 and peripheral mononuclear blood cells (PMBCs) (CC50 > 35 μM and CC50 > 7 μM, respectively) compared to a much higher CC50 value in the case of CV-N (CC50 of 191 nM and 900 nM in MT-4 cells and PBMCs, respectively) [51]. It can be inferred, therefore, that MV-N has a greater potency against HIV-1 and a higher safety profile when compared to CV-N.
Scytovirin (SV-N) is a 9.71 kDa HIV-neutralizing protein initially isolated from the aqueous extracts of the cultured cyanobacterium, Scytonema varium [53]. The compound has a high affinity for mannose-rich oligosaccharides on the gp120 envelope, inducing blockage of the viral entry into the target cell [54][55]. Potent activity has been recorded for SV-N against various HIV-1 clinical isolates and laboratory strains, with EC50 values ranging between 0.4 and 394 nM, and 0.3 and 7 nM, respectively [56]. Recombinant SV-N (rSV-N) also inhibited cytopathicity induced by HIV in side-by-side in vitro XTT-based anti-HIV assays using CEM-SS host cells with an EC50 of 4.5 nM, while native SV-N EC50 values ranged between 0.3 and 7 nM [56][57]. The structures of the most active cyanobacteria-derived peptides are portrayed in Figure 3.
Marinedrugs 20 00477 g004 550
Figure 3. Chemical structures of MBAPs derived from marine cyanobacteria. (a) microvirin, and (b) scytovirin.

This entry is adapted from the peer-reviewed paper 10.3390/md20080477

References

  1. Muthu, M.; Gopal, J.; Chun, S.; Devadoss, A.J.P.; Hasan, N.; Sivanesan, I. Crustacean waste-derived chitosan: Antioxidant properties and future perspective. Antioxidants 2021, 10, 228.
  2. Chakrabarti, S.; Guha, S.; Majumder, K. Food derived bioactive peptides in human health: Challenges and opportunities. Nutrients 2018, 10, 1738.
  3. Martínez-Núñez, M.A.; López, V.E.L. Nonribosomal peptides synthetases and their applications in industry. Sustain. Chem. Process. 2016, 4, 13.
  4. Wang, X.; Yu, H.; Xing, R.; Li, P. Characterization, preparation and purification of marine bioactive peptides. Biomed Res. Int. 2017, 2017, 9746720.
  5. Le Gouic, A.; Harnedy, P.; Fitz Gerald, R. Bioactive peptides from fish protein byproducts. In Bioactive Molecules in Food, 1st ed.; Jean-Michel, M., Ramawat, K.G., Eds.; Springer: New York, NY, USA, 2018; pp. 1–35.
  6. Atef, M.; Chait, Y.A.; Ojagh, S.M.; Latifi, A.M.; Esmaeili, M.; Hammami, R.; Udenigwe, C.C. Anti-Salmonella activity and peptidomics profiling of peptide fractions produced from sturgeon fish skin collagen (Huso huso) using commercial enzymes. Nutrients 2021, 13, 2657.
  7. Kaufmann, B.; Christen, P. Recent extraction techniques for natural products: Microwave-assisted extraction and pressurised solvent extraction. Phytochem Anal. 2002, 13, 105–113.
  8. Grosso, C.; Valentão, P.; Ferreres, F.; Andrade, P.B. Alternative and efficient extraction methods for marine-derived compounds. Mar. Drugs 2015, 13, 3182–3230.
  9. Ersson, B.; Rydén, L.; Janson, J.C. Protein Purification: Principles, High Resolution Methods, and Applications, 3rd ed.; John Wiley & Sons Inc.: Hoboken, NJ, USA, 2011; pp. 1–22.
  10. Lee, J.W.; Jeffries, T.W. Efficiencies of acid catalysts in the hydrolysis of lignocellulosic biomass over a range of combined severity factors. Bioresour. Technol. 2011, 102, 5884–5890.
  11. Chen, J.P.; Mou, H.; Wang, L.K.; Matsuura, T. Membrane Filtration in Advanced Physicochemical Treatment Processes; Humana Press: Totowa, NJ, USA, 2006; pp. 203–259.
  12. Bai, C.; Wei, Q.; Ren, X. Selective extraction of collagen peptides with high purity from cod skins by deep eutectic solvents. ACS Sustain. Chem. Eng. 2017, 5, 7220–7227.
  13. Anbuchezian, R.; Ravichandran, S.; Karthick Rajan, D.; Tilivi, S.; Prabha-Devi, S. Identification and functional characterization of antimicrobial peptide from the marine crab Dromia dehaani. Microb. Pathog. 2018, 125, 60–65.
  14. Anand, M.; Alagar, M.; Ranjitha, J.; Selvaraj, V. Total synthesis and anticancer activity of a cyclic heptapeptide from marine sponge using water soluble peptide coupling agent EDC. Arab. J. Chem. 2019, 12, 2782–2787.
  15. Auwal, S.M.; Zainal Abidin, N.; Zarei, M.; Tan, C.P.; Saari, N. Identification, structure activity relationship and in silico molecular docking analyses of five novel angiotensin I-converting enzyme (ACE)-inhibitory peptides from stone fish (Actinopyga lecanora) hydrolysates. PLoS ONE 2019, 14, e0197644.
  16. Fan, X.; Cui, Y.; Zhang, R.; Zhang, X. Purification and identification of anti-obesity peptides derived from Spirulina platensis. J. Funct. Foods. 2018, 47, 350–360.
  17. Harnedy, P.A.; O’Keeffe, M.B.; FitzGerald, R.J. Fractionation and identification of antioxidant peptides from an enzymatically hydrolysed Palmaria palmata protein isolate. Int. Food Res. 2017, 100, 416–422.
  18. Xia, E.; Zhai, L.; Huang, Z.; Liang, H.; Yang, H.; Song, G.; Li, W.; Tang, H. Optimization and identification of antioxidant peptide from underutilized Dunaliella salina protein: Extraction, in vitro gastrointestinal digestion, and fractionation. Biomed Res. Int. 2019, 2019, 6424651.
  19. Xu, B.; Ye, L.; Tang, Y.; Zheng, J.; Tian, X.; Yang, Y.; Yang, Z. Preparation and purification of an immunoregulatory peptide from Stolephorus chinensis of the East Sea of China. Process Biochem. 2020, 98, 151–159.
  20. Sridhar, K.; Inbaraj, B.S.; Chen, B.H. Recent developments on production, purification and biological activity of marine peptides. Int. Food Res. 2021, 147, 110468.
  21. Anjum, K.; Abbas, S.Q.; Shah, S.A.A.; Akhter, N.; Batool, S.; Hassan, S.S. Marine sponges as a drug treasure. Biomol. Ther. 2016, 24, 347–362.
  22. Vitali, A. Antimicrobial peptides derived from marine sponges. Am. J. Clin. Microbiol. Antimicrob. 2018, 1, 1006.
  23. Wu, Q.; Nay, B.; Yang, M.; Ni, Y.; Wang, H.; Yao, L.; Li, X. Marine sponges of the genus Stelletta as promising drug sources: Chemical and biological aspects. Acta Pharm. Sin. B. 2019, 9, 237–257.
  24. Kang, H.K.; Seo, C.H.; Park, Y. Marine peptides and their anti-infective activities. Mar. Drugs 2015, 13, 618–654.
  25. Plaza, A.; Bifulco, G.; Masullo, M.; Lloyd, J.R.; Keffer, J.L.; Colin, P.L.; Hooper, J.N.; Bell, L.J.; Bewley, C.A. Mutremdamide A and koshikamides C-H, peptide inhibitors of HIV-1 entry from different Theonella species. J. Org. Chem. 2010, 75, 4344–4355.
  26. Agrawal, S.; Adholeya, A.; Deshmukh, S.K. The pharmacological potential of non-ribosomal peptides from marine sponge and tunicates. Front. Pharmacol. 2016, 7, 333.
  27. Kang, H.; Choi, M.; Seo, C.; Park, Y. Therapeutic properties and biological benefits of marine-derived anticancer peptides. Int. J. Mol. Sci. 2018, 19, 919.
  28. Macedo, M.W.F.S.; Cunha, N.B.; Carneiro, J.A.; Costa, R.A.; Alencar, S.A.; Cardoso, M.H.; Franco, O.L.; Dias, S.C. Marine organisms as a rich source of biologically active peptides. Front. Mar. Sci 2021, 8, 889.
  29. Oku, N.; Gustafson, K.R.; Cartner, L.K.; Wilson, J.A.; Shigematsu, N.; Hess, S.; Pannell, L.K.; Boyd, M.R.; McMahon, J.B. Neamphamide A, a new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge Neamphius huxleyi. J. Nat. Prod. 2004, 67, 1407–1411.
  30. Andavan, G.S.; Lemmens-Gruber, R. Cyclodepsipeptides from marine sponges: Natural agents for drug research. Mar. Drugs 2010, 8, 810–834.
  31. Vo, T.; Kim, S. Potential anti-HIV agents from marine resources: An overview. Mar. Drugs 2010, 8, 2871–2892.
  32. Zampella, A.; Sepe, V.; Bellotta, F.; Luciano, P.; D’Auria, M.; Cresteil, T. Homophymines B–E and A1–E1, a family of bioactive cyclodepsipeptides from the sponge Homophymia sp. Org. Biomol. Chem. 2009, 7, 4037–4044.
  33. Flores-Holguín, N.; Frau, J.; Glossman-Mitnik, D. Computational pharmacokinetics Report, ADMET study and conceptual DFT-based estimation of the chemical reactivity properties of marine cyclopeptides. Chem. Open 2021, 10, 1142–1149.
  34. Giordano, D.; Costantini, M.; Coppola, D.; Lauritano, C.; Núñez Pons, L.; Ruocco, N. Biotechnological applications of bioactive peptides from marine sources. Adv. Microb. Physiol. 2018, 73, 171–220.
  35. Sukmarini, L. Antiviral peptides (AVPs) of marine origin as propitious therapeutic drug candidates for the treatment of human viruses. Molecules 2022, 27, 2619.
  36. Shin, H.J.; Rashid, M.A.; Cartner, L.K.; Bokesch, H.R.; Wilson, J.A.; McMahon, J.B.; Gustafson, K.R. Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge Stelletta sp. Tetrahedron Lett. 2015, 56, 4215–4219.
  37. Ribeiro, R.; Pinto, E.; Fernandes, C.; Sousa, E. Marine cyclic peptides: Antimicrobial activity and synthetic strategies. Mar. Drugs 2022, 20, 397.
  38. Chun, T.W.; Moir, S.; Fauci, A.S. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat. Immunol. 2015, 16, 584–589.
  39. Wang, M.; Tietjen, I.; Chen, M.; Williams, D.E.; Daoust, J.; Brockman, M.A.; Andersen, R.J. Sesterterpenoids isolated from the sponge Phorbas sp. activate latent HIV-1 provirus expression. J. Org. Chem. 2016, 81, 11324–11334.
  40. Maina, E.K.; Adan, A.A.; Mureithi, H.; Muriuki, J.; Lwembe, R.M. A review of current strategies towards the elimination of latent HIV-1 and subsequent HIV-1 cure. Curr. HIV Res. 2021, 19, 14–26.
  41. Vansant, G.; Bruggemans, A.; Janssens, J.; Debyser, Z. Block-and-lock strategies to cure HIV infection. Viruses 2020, 12, 84.
  42. Richard, K.; Williams, D.E.; De Silva, E.D.; Brockman, M.A.; Brumme, Z.L.; Andersen, R.J.; Tietjen, I. Identification of novel HIV-1 latency-reversing agents from a library of marine natural products. Viruses 2018, 10, 348.
  43. Silipo, A.; Molinaro, A.; Molteni, M.; Rossetti, C.; Parrilli, M.; Lanzetta, R. Full structural characterization of an extracellular polysaccharide produced by the freshwater cyanobacterium Oscillatoria planktothrix. Eur. J. Org. Chem. 2010, 2010, 5594–5600.
  44. Fidor, A.; Konkel, R.; Mazur-Marzec, H. Bioactive peptides produced by cyanobacteria of the genus Nostoc: A review. Mar. Drugs 2019, 17, 561.
  45. Boyd, M.R.; Gustafson, K.R.; McMahon, J.B.; Shoemaker, R.H.; O’Keefe, B.R.; Mori, T.; Gulakowski, R.J.; Wu, L.; Rivera, M.I.; Laurencot, C.M.; et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob. Agents Chemother. 1997, 41, 1521–1530.
  46. Mazalovska, M.; Kouokam, J.C. Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections. Biomed Res. Int. 2018, 2018, 3750646.
  47. Agarwal, R.; Trivedi, J.; Mitra, D. High yield production of recombinant cyanovirin-N (antiviral lectin) exhibiting significant anti-HIV activity, from a rationally selected Escherichia coli strain. Process Biochem. 2020, 93, 1–11.
  48. Lotfi, H.; Sheervalilou, R.; Zarghami, N. An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development. Bioimpacts 2018, 8, 139–151.
  49. Woodham, A.W.; Skeate, J.G.; Sanna, A.M.; Taylor, J.R.; Da-Silva, D.M.; Cannon, P.M.; Kast, W.M. Human immunodeficiency virus immune cell receptors, coreceptors, and cofactors: Implications for prevention and treatment. AIDS Patient Care STDS 2016, 30, 291–306.
  50. Vamvaka, E.; Evans, A.; Ramessar, K.; Krumpe, L.R.; Shattock, R.J.; Keefe, B.R.; Christou, P.; Capell, T. Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro. Plant Cell Rep. 2016, 35, 1309–1319.
  51. Huskens, D.; Férir, G.; Vermeire, K.; Kehr, J.C.; Balzarini, J.; Dittmann, E.; Schols, D. Microvirin, a novel α (1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J. Biol. Chem. 2010, 285, 24845–24854.
  52. Shahid, M.; Qadir, A.; Yang, J.; Ahmad, I.; Zahid, H.; Mirza, S.; Windisch, M.P.; Shahzad-ul-Hussan, S. An engineered microvirin variant with identical structural domains potently inhibits human immunodeficiency virus and hepatitis C virus cellular entry. Viruses 2020, 12, 199.
  53. Armario-Najera, V.; Blanco-Perera, A.; Shenoy, S.R.; Sun, Y.; Marfil, S.; Muñoz-Basagoiti, J.; Perez-Zsolt, D.; Blanco, J.; Izquierdo-Useros, N.; Capell, T.; et al. Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1. Plant Cell Rep. 2022, 41, 1013–1023.
  54. Garrison, A.R.; Giomarelli, B.G.; Lear-Rooney, C.M.; Saucedo, C.J.; Yellayi, S.; Krumpe, L.R.; Rose, M.; Paragas, J.; Bray, M.; Olinger, G.G.; et al. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antivi. Res. 2014, 112, 1–7.
  55. Jones, T.H.; McClelland, E.E.; McFeeters, H.; McFeeters, R.L. Novel antifungal activity for the lectin scytovirin: Inhibition of Cryptococcus neoformans and Cryptococcus gattii. Front. Microbiol. 2017, 8, 755.
  56. Huskens, D.; Schols, D. Algal lectins as potential HIV microbicide candidates. Mar. Drugs 2012, 10, 1476–1497.
  57. Xiong, C.; O’Keefe, B.R.; Botos, I.; Wlodawer, A.; McMahon, J.B. Overexpression and purification of scytovirin, a potent, novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Protein Expr. Purif. 2006, 46, 233–239.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback